Interleukin-1 Inhibition to Improve the Response of Myeloproliferative Neoplasms Resistant to Cytoreductive Treatment (INTEREST)
Myeloproliferative neoplasms (MPNs) - polycythemia vera, essential thrombocythemia, and primary myelofibrosis - are characterized by excessive myeloid proliferation driven by mutations affecting the JAK2, CALR, and MPL genes, resulting in constitutive activation of hematopoietic cytokine signaling pathways. These hematological malignancies carry an increased risk of thrombosis and may evolve toward secondary myelofibrosis or acute leukemia. Bone marrow inflammation, particularly through interleukin-1 (IL-1), plays a major role in clonal expansion and the clinical expression of these diseases, as demonstrated by preclinical models showing the beneficial effect of its inhibition.
Anakinra, an IL-1 receptor antagonist widely used in rheumatology but never evaluated in MPNs, represents a promising therapeutic option. This proof-of-concept study will randomize 50 patients with a suboptimal response to cytoreductive therapy into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or cytoreductive therapy alone (n=25). The primary endpoint will be the reduction in serum calprotectin levels, a key inflammatory marker of the IL-1 loop that has recently demonstrated prognostic relevance in MPNs. Secondary endpoints will include improvements in hematological parameters, driver mutation allelic burden, pro-inflammatory cytokines, and quality of life.
This study represents an essential step toward larger trials aimed at demonstrating a durable reduction in thrombotic risk and disease progression.
調査の概要
詳細な説明
Eligible patients will be identified during routine follow-up visits. After signature of informed consent and confirmation of all eligibility criteria - including a negative urine pregnancy test for women of childbearing potential - patients will be randomized into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or ongoing cytoreductive therapy alone (n=25), for a duration of 3 months.
Clinical and laboratory assessments (CBC, CRP, circulating CD34+ cells, allelic burden, calprotectin, cytokines, quality of life) will be performed at baseline, at 3 months, and at 6 months. An additional visit at 1 month is planned in the anakinra arm to assess tolerability. Patients may withdraw at any time, with reasons documented in the eCRF.
The addition of an anti-IL-1 treatment to cytoreductive therapy could improve its efficacy by promoting control of the mutated clone, which is poorly targeted by current cytoreductive agents other than interferon-α, often poorly tolerated. Better clonal control could limit phenotypic progression, reduce thrombotic risk, and improve hematological response, particularly in the megakaryocytic lineage.
The impact on myelofibrosis, observed in mice, and the improvement in quality of life through reduction of systemic inflammation remain to be confirmed in humans. Not all patients will necessarily benefit from this approach, justifying this exploratory study to evaluate its potential and feasibility.
The risks associated with anakinra are predictable and well documented (local reactions, minor systemic effects, infectious risk), mitigated by the short treatment duration and close monitoring. The benefit-risk ratio is considered favorable.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Eric LIPPERT, Pr
- 電話番号:0229247037
- メール:eric.lippert@chu-brest.fr
研究場所
-
-
-
Angers、フランス、49000
- Chu Angers
-
コンタクト:
- Françoise BOYER, Dr
- メール:Frboyer@chu-angers.fr
-
Brest、フランス、29200
- CHU de Brest
-
コンタクト:
- Jean-Christophe IANOTTO, Pr
- 電話番号:02 98 22 33 15
- メール:jean-christophe.ianotto@chu-brest.fr
-
Morlaix、フランス、29600
- Ch Pays de Morlaix
-
コンタクト:
- Christophe NICOL, Dr
- 電話番号:02 98 62 60 38
- メール:Cnicol@ch-morlaix.fr
-
Paris、フランス、75475
- APHP
-
コンタクト:
- Jean-Jacques KILADJIAN, Pr
- 電話番号:01 42 49 94 18
- メール:jean-jacques.kiladjian@aphp.fr
-
Tours、フランス、37044
- Chu Tours
-
コンタクト:
- Antoine MACHET, Dr
- 電話番号:02 47 47 37 12
- メール:A.machet@chu-tours.fr
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Diagnosis of MPN: PV, ET, or PMF according to WHO criteria
- Stable cytoreductive therapy for at least 6 months
- Incomplete hematologic response according to ELN criteria, excluding bone marrow, OR complete hematologic response with anemia in ET, OR persistence of general clinical symptoms (fever, night sweats, pruritus, fatigue > 5/10 on VAS)
- Adult patient capable of providing informed consent
Exclusion Criteria:
- Recurrent or poorly controlled infections
- Thrombocytopenia < 100 G/L
- Neutropenia < 1 G/L
- Hypersensitivity to the active substance, any excipients, or proteins derived from Escherichia coli
- Concomitant immunosuppressive therapy
- Refusal to participate
- Patient under legal protection (guardianship, curatorship, etc.)
- Patients unable to consent.
- Positive urine pregnancy test at screening / pregnant or breastfeeding women.
- Lack of understanding of questionnaires or inability to follow up.
- Women of childbearing potential unwilling to use a highly effective contraceptive methods
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Anakinra + cytoreductive therapy
Anakinra 100 mg/day subcutaneously for 3 months, added to ongoing standard cytoreductive therapy (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. Additional Month 1 safety/tolerability visit (clinical exam, routine biology, AE/SAE and injection-site reaction review, compliance check) and an injection diary for adherence. |
Recombinant human interleukin-1 receptor antagonist (Kineret 100 mg/0.67 mL prefilled syringe). Administered at 100 mg once daily by subcutaneous injection for 3 months, in addition to ongoing standard cytoreductive therapy. Self-injection or home-nurse administration; adherence tracked via injection diary. |
|
介入なし:Cytoreductive therapy alone
Standard cytoreductive therapy continued alone, with no additional study treatment (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. No Month 1 visit. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in serum calprotectin levels
時間枠:Baseline and Month 3
|
Calprotectin levels are measured on serum samples by centralized analysis (µg/mL) |
Baseline and Month 3
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Improvement (yes/no) of the response status between baseline and month 3.
時間枠:Month 3
|
Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013). |
Month 3
|
|
Improvement (yes/no) of the response status between baseline and month 6.
時間枠:Month 6
|
Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013). |
Month 6
|
|
Improvement (yes/no) of the response status between month 3 and month 6.
時間枠:Month 6
|
Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013). |
Month 6
|
|
Hemoglobin count
時間枠:Baseline
|
Measurement of Hemoglobin in g/dL |
Baseline
|
|
Hematocrit count
時間枠:Baseline
|
Measurement of Hematocrit in % |
Baseline
|
|
White blood cell count
時間枠:Baseline
|
Measurement of WBC in G/L |
Baseline
|
|
Platelet cell count
時間枠:Baseline
|
Measurement of Platelets in G/L |
Baseline
|
|
Hemoglobin count
時間枠:Month 3
|
Measurement of Hemoglobin in g/dL |
Month 3
|
|
Hematocrit count
時間枠:Month 3
|
Measurement of Hematocrit in % |
Month 3
|
|
White blood cell count
時間枠:Month 3
|
Measurement of WBC in G/L |
Month 3
|
|
Platelet cell count
時間枠:Month 3
|
Measurement of Platelets in G/L |
Month 3
|
|
Hemoglobin count
時間枠:Month 6
|
Measurement of Hemoglobin in g/dL |
Month 6
|
|
Hematocrit count
時間枠:Month 6
|
Measurement of Hematocrit in % |
Month 6
|
|
White blood cell count
時間枠:Month 6
|
Measurement of WBC in G/L |
Month 6
|
|
Platelet cell count
時間枠:Month 6
|
Measurement of Platelets in G/L |
Month 6
|
|
Treatment-related adverse event for experimental group
時間枠:Month 1
|
A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria). |
Month 1
|
|
Treatment-related adverse event for experimental group
時間枠:Month 3
|
A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria). |
Month 3
|
|
Treatment-related adverse event for experimental group
時間枠:Month 6
|
A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria). |
Month 6
|
|
Adherence to treatment regimen for experimental group
時間枠:Month 1
|
Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between baseline and month 1. Days with missing diary entries will be excluded from the calculation. |
Month 1
|
|
Adherence to treatment regimen for experimental group
時間枠:Month 2
|
Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 1 and month 2. Days with missing diary entries will be excluded from the calculation |
Month 2
|
|
Adherence to treatment regimen for experimental group
時間枠:Month 3
|
Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 2 and month 3. Days with missing diary entries will be excluded from the calculation. |
Month 3
|
|
QLQ-C30 Summary Score
時間枠:Baseline
|
The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome. |
Baseline
|
|
QLQ-C30 Summary Score
時間枠:Month 3
|
The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome. |
Month 3
|
|
QLQ-C30 Summary Score
時間枠:Month 6
|
The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome. |
Month 6
|
|
Global health status / QoL score
時間枠:Baseline
|
Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life. |
Baseline
|
|
Global health status / QoL score
時間枠:Month 3
|
Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life. |
Month 3
|
|
Global health status / QoL score
時間枠:Month 6
|
Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life. |
Month 6
|
|
Patient-reported symptom severity over the previous 4 weeks for pruritus
時間枠:Baseline
|
Defined as the score on a 10-point Visual Analog Scale |
Baseline
|
|
Patient-reported symptom severity over the previous 4 weeks for fever
時間枠:Baseline
|
Defined as the score on a 10-point Visual Analog Scale |
Baseline
|
|
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
時間枠:Baseline
|
Defined as the score on a 10-point Visual Analog Scale |
Baseline
|
|
Patient-reported symptom severity over the previous 4 weeks for pruritus
時間枠:Month 3
|
Defined as the score on a 10-point Visual Analog Scale |
Month 3
|
|
Patient-reported symptom severity over the previous 4 weeks for fever
時間枠:Month 3
|
Defined as the score on a 10-point Visual Analog Scale |
Month 3
|
|
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
時間枠:Month 3
|
Defined as the score on a 10-point Visual Analog Scale |
Month 3
|
|
Patient-reported symptom severity over the previous 4 weeks for pruritus
時間枠:Month 6
|
Defined as the score on a 10-point Visual Analog Scale |
Month 6
|
|
Patient-reported symptom severity over the previous 4 weeks for fever
時間枠:Month 6
|
Defined as the score on a 10-point Visual Analog Scale |
Month 6
|
|
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
時間枠:Month 6
|
Defined as the score on a 10-point Visual Analog Scale |
Month 6
|
|
Inflammatory biological profile
時間枠:Baseline
|
Measurement of IL-1β cytokines in pg/mL. |
Baseline
|
|
Inflammatory biological profile
時間枠:Month 3
|
Measurement of IL-1β cytokines in pg/mL. |
Month 3
|
|
Inflammatory biological profile
時間枠:Month 6
|
Measurement of IL-1β cytokines in pg/mL. |
Month 6
|
|
Inflammatory biological profile
時間枠:Baseline
|
Measurement of IL-6 cytokines in pg/mL. |
Baseline
|
|
Inflammatory biological profile
時間枠:Month 3
|
Measurement of IL-6 cytokines in pg/mL. |
Month 3
|
|
Inflammatory biological profile
時間枠:Month 6
|
Measurement of IL-6 cytokines in pg/mL. |
Month 6
|
|
Inflammatory biological profile
時間枠:Baseline
|
Measurement of IL-8 cytokines in pg/mL. |
Baseline
|
|
Inflammatory biological profile
時間枠:Month 3
|
Measurement of IL-8 cytokines in pg/mL. |
Month 3
|
|
Inflammatory biological profile
時間枠:Month 6
|
Measurement of IL-8 cytokines in pg/mL. |
Month 6
|
|
Inflammatory biological profile
時間枠:Baseline
|
Measurement of MIP-1β cytokines in pg/mL. |
Baseline
|
|
Inflammatory biological profile
時間枠:Month 3
|
Measurement of MIP-1β cytokines in pg/mL. |
Month 3
|
|
Inflammatory biological profile
時間枠:Month 6
|
Measurement of MIP-1β cytokines in pg/mL. |
Month 6
|
|
Inflammatory biological profile
時間枠:Baseline
|
Measurement of TNF-α cytokines in pg/mL. |
Baseline
|
|
Inflammatory biological profile
時間枠:Month 3
|
Measurement of TNF-α cytokines in pg/mL. |
Month 3
|
|
Inflammatory biological profile
時間枠:Month 6
|
Measurement of TNF-α cytokines in pg/mL. |
Month 6
|
|
Allele burden of the driver mutation
時間枠:Baseline
|
Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification. |
Baseline
|
|
Allele burden of the driver mutation
時間枠:Month 3
|
Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification. |
Month 3
|
|
Allele burden of the driver mutation
時間枠:Month 6
|
Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification. |
Month 6
|
|
Allele burden of the driver mutation
時間枠:Baseline
|
Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification. |
Baseline
|
|
Allele burden of the driver mutation
時間枠:Month 3
|
Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification. |
Month 3
|
|
Allele burden of the driver mutation
時間枠:Month 6
|
Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification. |
Month 6
|
|
Allele burden of the driver mutation
時間枠:Baseline
|
Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification. |
Baseline
|
|
Allele burden of the driver mutation
時間枠:Month 3
|
Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification. |
Month 3
|
|
Allele burden of the driver mutation
時間枠:Month 6
|
Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification. |
Month 6
|
|
Fibrosis markers
時間枠:Baseline
|
Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis. |
Baseline
|
|
Fibrosis markers
時間枠:Month 3
|
Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis. |
Month 3
|
|
Fibrosis markers
時間枠:Month 6
|
Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis. |
Month 6
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 29BRC25.0416
- 2025 (米国 NIH グラント/契約)
- 2025-523921-17-00 (Ctis)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。